Improving survival rates for patients with acute myeloid leukemia : Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
---|---|
Enthalten in: |
Current research in translational medicine - 68(2020), 4 vom: 27. Nov., Seite 145-148 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yafour, Nabil [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antilymphocyte Serum |
---|
Anmerkungen: |
Date Completed 06.10.2021 Date Revised 06.10.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.retram.2020.09.001 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315986115 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315986115 | ||
003 | DE-627 | ||
005 | 20231225160111.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.retram.2020.09.001 |2 doi | |
028 | 5 | 2 | |a pubmed24n1053.xml |
035 | |a (DE-627)NLM315986115 | ||
035 | |a (NLM)33028507 | ||
035 | |a (PII)S2452-3186(20)30055-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yafour, Nabil |e verfasserin |4 aut | |
245 | 1 | 0 | |a Improving survival rates for patients with acute myeloid leukemia |b Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.10.2021 | ||
500 | |a Date Revised 06.10.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Letter | |
650 | 7 | |a Antilymphocyte Serum |2 NLM | |
650 | 7 | |a Vidarabine |2 NLM | |
650 | 7 | |a FA2DM6879K |2 NLM | |
650 | 7 | |a Busulfan |2 NLM | |
650 | 7 | |a G1LN9045DK |2 NLM | |
650 | 7 | |a fludarabine |2 NLM | |
650 | 7 | |a P2K93U8740 |2 NLM | |
700 | 1 | |a Serradj, Faiza |e verfasserin |4 aut | |
700 | 1 | |a Osmani, Soufi |e verfasserin |4 aut | |
700 | 1 | |a Brahimi, Mohamed |e verfasserin |4 aut | |
700 | 1 | |a Bouhass, Rachid |e verfasserin |4 aut | |
700 | 1 | |a Arabi, Abdessamad |e verfasserin |4 aut | |
700 | 1 | |a Bazarbachi, Ali |e verfasserin |4 aut | |
700 | 1 | |a Bekadja, Mohamed Amine |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current research in translational medicine |d 2016 |g 68(2020), 4 vom: 27. Nov., Seite 145-148 |w (DE-627)NLM259979007 |x 2452-3186 |7 nnns |
773 | 1 | 8 | |g volume:68 |g year:2020 |g number:4 |g day:27 |g month:11 |g pages:145-148 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.retram.2020.09.001 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 68 |j 2020 |e 4 |b 27 |c 11 |h 145-148 |